Updated on 20 September 2016
GE plans to establish four prefabricated, off-the-shelf biologics factories for GE customers in GE BioPark Cork
Singapore: Ireland's Minister for Jobs, Enterprise and Innovation, Mary Mitchell O'Connor TD, has announced that GE is to invest €150 million in a new biopharmaceutical manufacturing campus on Industrial Development Agency (IDA) Ireland's strategic site at Loughbeg, Ringaskiddy, Co. Cork.
GE BioPark Cork, subject to contract and planning approvals, will feature Europe's first KUBio, prefabricated, off-the-shelf bio-manufacturing facilities, owned and run by GE customers, and will serve as focal point for further investment in next-generation biopharmaceutical manufacturing in Ireland.
GE BioPark Cork is expected to be home to more than 500 new jobs when fully operational; 400 with biopharma companies and a further 100 employed directly by GE. The construction phase, subject to planning approvals, is expected to begin by mid- 2017 and create up to 800 construction jobs. The project is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
To further develop biopharma manufacturing skills and expertise in Ireland, GE and the National Institute for Bioprocessing Research and Training (NIBRT) also announced their plan to create a NIBRT-GE Single-use Centre of Excellence at NIBRT's Dublin facility. NIBRT expects to train up to 1,500 bioprocessing professionals annually on next-generation biologic manufacturing technologies. These exceptional technologies for biopharma manufacturing will be used in GE BioPark Cork's manufacturing facilities.
GE BioPark Cork will be a GE-managed campus including four fully-equipped KUBio factories owned by independent biopharma companies manufacturing proprietary medicines, with GE running centralised shared utilities and site services.